Influence of treatment with onapristone on the IGF-system in breast cancer patients

Journal of Steroid Biochemistry and Molecular Biology

Volumn 66, Issue 3, 1998, Pages 159-163

  Helle, Svein I ^a   Jonat, Walter ^b   Giurescu, Marius ^c   Ekse, Dagfinn ^a   Holly, Jeff M P ^d   Lønning, Per E ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF KIEL   (Germany)

^c BAYER PHARMA AG   (Germany)

^d BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; HYDROCORTISONE; MEDROXYPROGESTERONE; ONAPRISTONE; SOMATOMEDIN BINDING PROTEIN 1;

ADULT; AGED; ARTICLE; BIOAVAILABILITY; BREAST CANCER; CLINICAL ARTICLE; DRUG EFFECT; ENZYME INHIBITION; FEMALE; GROWTH INHIBITION; HORMONAL THERAPY; HUMAN; LIGAND BINDING; POSTMENOPAUSE; PROTEIN DEGRADATION;

ADULT; AGED; ANDROSTENEDIONE; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; FEMALE; GONANES; HORMONE ANTAGONISTS; HUMANS; HYDROCORTISONE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 4; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MIDDLE AGED; NEOPLASM METASTASIS; POSTMENOPAUSE;

EID: 17744413078     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(98)00046-6     Document Type: Article

References (26)

1. Lønning P. E., Lien E. A. Mechanisms of action of endocrine treatment of breast cancer. Crit. Rev. Oncol./Hematol. 21:1995;158-193.
2. Lundgren S. Progestins in advanced breast cancer treatment. A review. Acta Oncol. 31:1992;709-722.
3. Lundgren S., Helle S. I., Lønning P. E. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients. Clin. Cancer Res. 2:1996;1515-1521.
4. Frost V. J., Helle S. I., Lønning P. E., van der Stappen J. W. J., Holly J. M. P. Effects of treatment with megestrol acetate, aminoglutethimide or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs) and IGFBP-3 protease status in patients with advanced breast cancer. J. Clin. Endocrinol. Metab. 81:1996;2216-2221.
5. Reed M. J., Christodoulides A., Koistinen R., Säppelä M., Teale J. D., Ghilchik M. W. The effect of endocrine therapy with medroxyprogesterone acetate, 4-hydroxyandrostenedione or tamoxifen on plasma concentrations of insulin-like growth factor (IGF)-I, IGF-II and IGFBP-1 in women with advanced breast cancer. Int. J. Cancer. 52:1992;208-212.
6. Karey K. P., Sirbasku D. A. Differential responsiveness of human breast cancer cell lines MCF-7 and T47D to growth factors and 17β-estradiol. Cancer Res. 48:1988;4083-4092.
7. Miell J. P., Taylor A. M., Jones J., Holly J. M. P., Gaillard R. C., Pralong F. P., Ross R. J. M., Blum W. F. The effects of dexamethasone treatment on immunoreactive and bioactive insulin-like growth factors (IGFs) and IGF-binding proteins in normal male volunteers. J. Endocrinol. 136:1993;525-533.
8. Bakker G. H., Setyono-Han B., Henkelman M. S., de Jong F. H., Lamberts S. W. J., van der Schoot P., Klijn J. G. M. Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in the treatment of rat mammary tumors. Cancer Treat. Rep. 71:1987;1021-1027.
9. Gill P. G., Vignon F., Bardon S., Derocq D., Rochefort H. Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells. Breast Cancer Res. Treat. 10:1987;37-45.
10. Classen S., Possinger K., Pelka-Fleischer R., Wilmanns W. Effect of onapristone and medroxyprogesterone acetate on the proliferation and hormone receptor concentration of human breast cancer cells. J. Steroid Biochem. Molec. Biol. 45:1993;315-319.
11. Schneider M. R., Michna H., Nishino Y., El Etreby M. F. Antitumor activity and mechanisms of action of different antiprogestins in experimental breast cancer models. J. Steroid Biochem. Molec. Biol. 37:1990;783-787.
12. Michna H., Schneider M. R., Nishino Y., El Etreby M. F. Antitumor activity of the antiprogestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse primary mammary tumors: mechanistic studies. Breast Cancer Res. Treat. 14:1989;275-288.
13. Michna H., Schneider M., Nishino Y., El Etreby M. F., McGuire W. L. Progesterone antagonists block the growth of experimental mammary tumors in G0/G1. Breast Cancer Res. Treat. 17:1990;155-156.
14. Holly J. M. P., Biddlecombe R. A., Dunger D. B., Edge J. A., Amiel S. A., Howell R., Chard T., Rees L. H. Circadian variation of GH-independent IGF-binding protein in diabetes mellitus and its relationship to insulin. A new role for insulin. Clin. Endocrinol. 29:1988;667-675.
15. Davies S. C., Wass J. A. H., Ross R. J. M., Cotterill A. M., Buchanan C. R., Coulson V. J., Holly J. M. P. The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness. J. Endocrinol. 130:1991;469-473.
16. Hossenlopp P., Seurin D., Segovia-Quinson B., Lassarre C., Hardouin S., Binoux M. Analysis of serum insulin-like growth factor binding proteins using Western ligand blotting: use of the method of titration of the binding proteins in competitive binding studies. Anal. Biochem. 154:1986;138-143.
17. Helle S. I., Holly J. M. P., Tally M., Hall K., van der Stappen J., Lønning P. E. Influence of treatment with tamoxifen and change in tumour burden on the IGF-system in breast cancer patients. Int. J. Cancer. 69:1996;335-339.
18. Hussain M. A., Schmitz O., Mengel A., Keller A., Christiansen J. S., Zapf J., Froesch E. R. Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans. J. Clin. Invest. 92:1993;2249-2256.
19. Mathieu M., Rochefort H., Barenton B., Prebois C., Vignon F. Interactions of cathepsin-D and insulin-like growth factor-II (IGF-II) on the IGF-II/mannose-6-phosphate receptor in human breast cancer cells and possible consequences on mitogenic activity of IGF-II. Mol. Endocrinol. 4:1990;1327-1335.
20. Peyrat J.-P., Bonneterre J., Beuscart R., Djiane J., Demaille A. Insulin-like growth factor receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res. 48:1988;6429-6433.
21. Jones J. I., Clemmons D. R. Insulin-like growth factors and their binding proteins: biological actions. Endocrine Rev. 16:1995;3-34.
22. Holly J. M. P., Claffey D. C. P., Cwyfan-Hughes S. C., Frost V. J., Yateman M. E. Proteases acting on IGFBPs: their occurrence and physiological significance. Growth Regul. 3:1993;88-91.
23. Blat C., Villaudy J., Binoux M. In vivo proteolysis of serum insulin-like growth factor (IGF) binding protein-3 results in increased availability of IGF to target cells. J. Clin. Invest. 93:1994;2286-2290.
24. Kanety H., Madjar Y., Dagan Y., Levi J., Papa M. Z., Pariente C., Goldwasser B., Karasik A. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J. Clin. Endocrinol. Metab. 77:1993;229-233.
25. Cohen P., Peehl D. M., Stamey T. A., Wilson K. F., Clemmons D. R., Rosenfeld R. G. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J. Clin. Endocrinol. Metab. 76:1993;1031-1035.
26. Young S. C. J., Underwood L. E., Celniker A., Clemmons D. R. Effects of recombinant insulin-like growth factor-I (IGF-I) and growth hormone on serum IGF-binding proteins in calorically restricted adults. J. Clin. Endocrinol. Metab. 75:1992;603-608.